otenabant (cp-945598) (Pfizer Inc)
Structured Review

Otenabant (Cp 945598), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/cp+945+598/pmc10531241-138-1-17
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention"
Article Title: Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
Journal: Hepatology Communications
doi: 10.1097/HC9.0000000000000234
Figure Legend Snippet: Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Techniques Used:
Related Articles
other:Article Title: Glucokinase activators and methods of using same Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compound of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-pyrazole-1-carboximidamide (SLV 319), Article Title: Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators Article Snippet: 5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopeptidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), nitrates, central alpha agonists (e.g., clonidine), alpha1 blockers (e.g., prazosine), arterial vasodilators (e.g., minoxidil), sympatolytics (e.g., resperine), renin inhibitors (e.g., Aliskiren (Novartis)). Article Title: [6,5]—bicyclic GPR119 G protein-coupled receptor agonists Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-Pyrazole-1-carboximidamide (SLV 319), Article Title: Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors Article Snippet: Cannabinoid receptor I antagonists and inverse agonists which may be optionally employed in combination with compounds of the present invention include rimonabant, SLV 319, Article Title: Pyridone GPR119 G protein-coupled receptor agonists Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-Pyrazole-1-carboximidamide (SLV 319), Article Title: Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators Article Snippet: Patents, 14:1435-1452 (2004)); a beta 3 adrenergic agonist (e.g., rafabegron (AJ9677, Takeda/Dainippon), N-[4-[2-[[(2S)-3-[(6-amino-3-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]phenyl]-4-(1-methylethyl)-benzenesulfonamide (L750355, Merck), or Article Title: Bicyclic heteroaryl compounds as GPR119 modulators Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-pyrazole-1-carboximidamide (SLV 319), Article Title: Therapeutic peptides Article Snippet: Combinations together with the following compounds are also contemplated as embodiments of the current invention: |

